abstract |
New Eglin mutants, which differ from the natural Eglins B and C in that one, two or three amino acids have been replaced by other amino acids in the area of the active center (amino acids 45 and 46, Leu-Asp). The mutants that can be produced using recombinant genetic engineering have valuable pharmacological properties. |